NCT00733811View on ClinicalTrials.gov

Efficacy Study of the Use of Sequential DFP-DFO Versus DFP

PHASE4CompletedINTERVENTIONAL

Enrollment

213

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Beta-ThalassemiaThalassemia Major

Interventions

DRUG

Deferiprone (DFP) and Deferoxamine (DFO)

Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week

DRUG

Deferiprone (DFP)

DFP alone at 75 mg/kg divided into three oral daily doses

Trial Locations (1)

Unknown

Ao V. Cervello, Palermo

All Listed Sponsors

lead

Azienda Ospedaliera V. Cervello

OTHER

NCT00733811 - Efficacy Study of the Use of Sequential DFP-DFO Versus DFP | Biotech Hunter | Biotech Hunter